Hematologic Cancers

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

Clonal hematopoiesis did not occur significantly more often among patients who received hematopoietic stem cell transplantation than their donors, according to findings of a correlative laboratory study.

A novel therapeutic approach may improve the persistence and functionality of chimeric antigen receptor T cells, helping to prevent relapse.

Older cancer survivors exhibited increased risk for cardiovascular disease than cancer-free individuals of the same age, according to a secondary analysis of a randomized study.

Use of post-transplant cyclophosphamide prophylaxis to prevent graft-versus-host disease could greatly expand access to hematopoietic stem cell transplantation, according to results of a retrospective study.

A first-in-human clinical trial will assess the safety of a personalized vaccine to treat diffuse hemispheric glioma, an aggressive brain tumor.

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

Deleting the CD5 gene from chimeric antigen receptor T cells improved their expansion, durability and tumor-killing capabilities, according to study findings.

New guidelines for vaccinating adults with solid or hematologic cancers detailed the importance of vaccination optimization, multidisciplinary coordination and vaccination of household members.

An innovative combination of drug sensitivity testing and genomics helped identify therapeutic options for children with relapsed or refractory solid or hematologic malignancies, according to results published in Nature Medicine.